Semmax Financial Advisors Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,259 shares of the company’s stock, valued at approximately $421,000.
Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares during the period. Vanguard Group Inc lifted its stake in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares during the period. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 1.9% during the fourth quarter. BlackRock Inc. now owns 182,903,344 shares of the company’s stock valued at $23,603,679,000 after buying an additional 3,486,924 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in shares of Johnson & Johnson by 11,576.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 74,757,633 shares of the company’s stock valued at $579,000 after buying an additional 74,117,373 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 36,364,874 shares of the company’s stock valued at $4,685,372,000 after buying an additional 2,741,351 shares during the period. 66.90% of the stock is currently owned by institutional investors.
In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.23% of the company’s stock.
NYSE:JNJ opened at $141.68 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. The company has a market cap of $371.12 billion, a price-to-earnings ratio of 17.32, a P/E/G ratio of 2.42 and a beta of 0.70. Johnson & Johnson has a fifty-two week low of $120.11 and a fifty-two week high of $148.99.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. Johnson & Johnson’s revenue was up .1% on a year-over-year basis. During the same quarter last year, the firm posted $2.06 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th were paid a dividend of $0.95 per share. The ex-dividend date was Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.68%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Hedge Funds Explained
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.